ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1214

Vonafexor in Progressive Alport Syndrome: Early Evidence of Kidney Function Benefit from the ALPESTRIA-1 Trial

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases

Authors

  • Knebelmann, Bertrand, Université Paris Cité, AP-HP, Paris, Île-de-France, France
  • Martinez Jimenez, Víctor, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
  • Silva, Arnold L., Boise Kidney, Boise, Idaho, United States
  • Mehta, Ankit, Baylor University Medical Center, Dallas, Texas, United States
  • Wallace, Eric L., The University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Simon, James F., Cleveland Clinic, Cleveland, Ohio, United States
  • Rastogi, Anjay, University of California Los Angeles, Los Angeles, California, United States
  • Pérez Gómez, María Vanessa, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
  • Torra, Roser, Fundacio Puigvert, Barcelona, CT, Spain
  • Udani, Suneel M., Nephrology Associates, Oak Park, Illinois, United States
  • Rigothier, Claire, Universite de Bordeaux, Bordeaux, Nouvelle-Aquitaine, France
  • Le Quintrec, Moglie, Hopital Lapeyronie, Montpellier, Occitanie, France
  • Wolf, Myles, Weill Cornell Medicine, New York, New York, United States
  • Vonderscher, Jacky, ENYO Pharma SA, Lyon, Auvergne-Rhône-Alpes , France
  • Girma, Hugo, ENYO Pharma SA, Lyon, Auvergne-Rhône-Alpes , France
  • Scalfaro, Pietro, ENYO Pharma SA, Lyon, Auvergne-Rhône-Alpes , France
Background

Alport syndrome (AS), the second most common genetic kidney disease, is marked by proteinuria and progressive kidney function loss, with no approved disease-modifying therapy. Standard of care (SOC) only modestly slows eGFR decline. Vonafexor, a selective farnesoid X receptor (FXR) agonist, modulates bile/lipid metabolism and has shown antifibrotic and anti-inflammatory effects in AS and CKD mouse models

Methods

This 24-week, single-arm, open-label phase 2 study evaluated vonafexor’s efficacy and safety in progressive AS (UACR >300 mg/g; eGFR 30–90 mL/min/1.73m2). It was given on top of stable SOC as daily fixed escalating doses: 25 mg (4 wks), 50 mg (4 wks), 100 mg (16 wks), followed by 12 wks off-treatment. Patients had 13 scheduled assessments; data were analyzed using a Mixed Model for Repeated Measures. We report preliminary on-treatment results.

Results

Of 36 screened, 26 patients with X-linked, autosomal, or digenic AS (14F/12M; age 22–53 yr) were enrolled at 12 US/EU sites. Baseline UACR was 859 ± 548 mg/g (mean ± SD) and eGFR 54.7 ± 18.7 mL/min/1.73m2. Early GGT reductions confirmed FXR engagement. Added to stable SOC (88% RAS blockade; 81% SGLT2i), vonafexor improved kidney function: the historical pre-baseline eGFR slope over 3 yr was –5.6 mL/min/1.73m2/yr (95% CI –8.5 to –2.8), whereas the on-treatment annualized slope to wk 24 was +7.0 (95% CI –0.6 to 14.5; p = 0.0008). UACR remained stable, with mean values [95%CI] of 659 mg/g [421;897] at wk 4, 941 [715;1169] at wk 8, and 790 [602;978] at wk 24 (p > 0.05 from baseline). Safety was consistent with prior trials: 20 patients (77%) reported 57 related AEs, mainly skin (11; 42%), GI (9; 35%), or lab abnormalities (7; 27%); most were mild (67%) or moderate (28%), 3 severe (5%). Five discontinued early: 2 hepatitis (adjudication ongoing), 2 pruritus, 1 epistaxis.

Conclusion

Vonafexor remarkably reversed the eGFR decline noted in AS patients despite stable SoC. This improvement occurred without a concomitant rise in UACR. The dissociation of eGFR recovery from proteinuria argues against a purely hemodynamic effect and supports a potential disease-modifying effect. A phase 3 trial is in preparation.

Funding

  • Commercial Support – ENYOPharma SA

Digital Object Identifier (DOI)